United Therapeutics Corp (UTHR)
264.32
-1.58
(-0.60%)
USD |
NASDAQ |
May 10, 16:00
264.32
0.00 (0.00%)
After-Hours: 20:00
United Therapeutics Enterprise Value: 9.690B for May 9, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 09, 2024 | 9.690B |
| May 08, 2024 | 9.476B |
| May 07, 2024 | 9.703B |
| May 06, 2024 | 9.450B |
| May 03, 2024 | 9.534B |
| May 02, 2024 | 9.345B |
| May 01, 2024 | 9.212B |
| April 30, 2024 | 8.289B |
| April 29, 2024 | 8.463B |
| April 26, 2024 | 8.265B |
| April 25, 2024 | 8.358B |
| April 24, 2024 | 8.405B |
| April 23, 2024 | 8.286B |
| April 22, 2024 | 8.268B |
| April 19, 2024 | 8.440B |
| April 18, 2024 | 8.395B |
| April 17, 2024 | 8.324B |
| April 16, 2024 | 8.167B |
| April 15, 2024 | 8.313B |
| April 12, 2024 | 8.174B |
| April 11, 2024 | 8.379B |
| April 10, 2024 | 8.404B |
| April 09, 2024 | 8.370B |
| April 08, 2024 | 8.367B |
| April 05, 2024 | 8.217B |
| Date | Value |
|---|---|
| April 04, 2024 | 8.233B |
| April 03, 2024 | 8.112B |
| April 02, 2024 | 7.996B |
| April 01, 2024 | 7.982B |
| March 31, 2024 | 8.047B |
| March 28, 2024 | 8.516B |
| March 27, 2024 | 9.154B |
| March 26, 2024 | 9.370B |
| March 25, 2024 | 9.200B |
| March 22, 2024 | 8.901B |
| March 21, 2024 | 8.855B |
| March 20, 2024 | 8.846B |
| March 19, 2024 | 8.972B |
| March 18, 2024 | 8.716B |
| March 15, 2024 | 8.801B |
| March 14, 2024 | 8.911B |
| March 13, 2024 | 9.060B |
| March 12, 2024 | 9.323B |
| March 11, 2024 | 9.447B |
| March 08, 2024 | 9.143B |
| March 07, 2024 | 8.998B |
| March 06, 2024 | 8.857B |
| March 05, 2024 | 8.520B |
| March 04, 2024 | 8.470B |
| March 01, 2024 | 8.620B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
2.554B
Minimum
Jul 22 2019
10.97B
Maximum
Dec 09 2022
6.753B
Average
7.585B
Median
Feb 23 2022
Enterprise Value Benchmarks
| Liquidia Corp | 869.58M |
| Esperion Therapeutics Inc | 576.14M |
| Vertex Pharmaceuticals Inc | 97.95B |
| Heron Therapeutics Inc | 535.31M |
| Aldeyra Therapeutics Inc | 116.85M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 306.60M |
| Revenue (Quarterly) | 677.70M |
| Total Expenses (Quarterly) | 321.40M |
| EPS Diluted (Quarterly) | 6.17 |
| Gross Profit Margin (Quarterly) | 89.24% |
| Profit Margin (Quarterly) | 45.24% |
| Earnings Yield | 8.00% |
| Operating Earnings Yield | 9.56% |
| Normalized Earnings Yield | 8.001 |